17 Facts About AMRI Global


AMRI Global commenced operations with custom synthesis services in laboratory space provided by Siena College.

FactSnippet No. 1,965,004

In early 2001, AMRI Global began leasing space in 30 Corporate Circle, which was fitted out as discovery chemistry laboratory space.

FactSnippet No. 1,965,005

AMRI Global then purchased two buildings at 24 and 26 Corporate Circle.

FactSnippet No. 1,965,006

AMRI Global went on to establish offshore subsidiaries, which included the Albany Molecular Research Singapore Research Centre, Pte.

FactSnippet No. 1,965,007

AMRI Global acquired the Budapest operations of ComGenex in March 2006.

FactSnippet No. 1,965,008

AMRI Global acquired a number of API and chemical intermediates manufacturing facilities from Ariane Orgachem in Aurangabad, India in 2008 then in 2010 AMRI Global completed the acquisition of Excelsyn in Holywell, UK This facility underwent successful inspections by the US Food and Drug Association in June 2011, and the UK Medicines and Healthcare products Regulatory Agency in January 2012 allowing for the production of registered intermediates and APIs for human use.

FactSnippet No. 1,965,009

In November 2012, AMRI Global announced that it would close the Bothell, Washington, site and would transition the sites biology capabilities to Singapore.

FactSnippet No. 1,965,010

In December 2012, AMRI Global Rensselaer was awarded a $200,000 Empire State Development Corporation grant for the expansion of the diagnostic imaging agent project.

FactSnippet No. 1,965,011

AMRI Global completed an initial public offering in February 1999, raising $56.

FactSnippet No. 1,965,012

AMRI Global completed a secondary public offering in October 2000, generating further net proceeds of $119.

FactSnippet No. 1,965,013

AMRI Global continues to receive royalties on the sale of Allegra and Telfast products globally.

FactSnippet No. 1,965,014

In June 2014, AMRI Global acquired OsoBio Pharmaceuticals, a contract manufacturer specializing in aseptic filling, for $110 million.

FactSnippet No. 1,965,015

AMRI Global was weighed down with debt from recent acquisitions and was struggling to make a profit; the arrangement awaited approval of shareholders and regulators.

FactSnippet No. 1,965,016

In July 1997, AMRI Global received a $100,000 grant from the National Cancer Institute to “design and synthesize compounds that inhibit a class of enzymes responsible for regulation of the cell cycle”.

FactSnippet No. 1,965,017

AMRI Global then extended a deal in 2001 with Pfizer for three additional years to “provide chemistry, research, development and analytical services”.

FactSnippet No. 1,965,018

In October 2012, AMRI Global announced a five-year extension of an API supply agreement with Shire for an undisclosed product.

FactSnippet No. 1,965,019

In December 2012, AMRI Global announced a multi-year extension of a commercial supply relationship with GE Healthcare to provide Aminobisamide, a key intermediate used in several diagnostic imaging agents.

FactSnippet No. 1,965,020